Raymond James Financial
NNVC icon

Raymond James Financial’s NanoViricides NNVC Stock Holding History

Raymond James Financial’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44
Closed -$62 – 6116
2025
Q2 		$62 Buy
+44
New +$60 ﹤0.01% 6875

Other funds holding NNVC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

Raymond James Financial's NNVC Position: Q3 2025 in Review

Raymond James Financial sold out of NanoViricides (NNVC) in Q3 2025, closing a stake of 44 shares — an estimated $62 sold.

Raymond James Financial first reported a position in NNVC in Q2 2025 and held it in 1 quarter. The position peaked at $62 in Q2 2025. 35 funds tracked by Wall St. Rank hold NNVC as of Q3 2025.

  • Raymond James Financial reported no remaining NanoViricides position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 44 NanoViricides shares in Q3 2025, an estimated $62.
  • Raymond James Financial first reported a position in NanoViricides in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's NanoViricides position peaked at $62 in Q2 2025.
  • 35 funds tracked by Wall St. Rank held NanoViricides as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.